Advanced search
Publication Cover
Acta Cardiologica Volume 62, 2007 - Issue 5
Submit an article Journal homepage
3
Views
0
CrossRef citations to date
0
Altmetric
Articles

Cardiac troponin I release after transcatheter closure of the interatrial septum: a prospective study.

Tom VydtDepartments of Cardiology, AZ Middelheim, Antwerpen, Belgium.;Departments of Cardiology, University Hospitals, Leuven, Belgium.Correspondence[email protected]
,
Paul VermeerschDepartments of Cardiology, AZ Middelheim, Antwerpen, Belgium.
,
Bruno SchwagtenDepartments of Cardiology, AZ Middelheim, Antwerpen, Belgium.
&
Werner BudtsDepartments of Cardiology, University Hospitals, Leuven, Belgium.
Pages 467-471 | Received 05 Jul 2007, Accepted 12 Jul 2007, Published online: 23 May 2017

References

  • Adams JE III, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88: 101–6.
  • Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thomp-son C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–9.
  • Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Has-selblad V, Armstrong PW, Moliterno DJ, Calif RM, Topol EJ, Ohman EM. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Car-diol 2002; 39: 1738–44.
  • Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92: 987–93.
  • Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eck-man LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J2003; 145: 522–8.
  • Pees C, Haas NA, von der Beek J, Ewert P, Berger F, Lange PE. Cardiac troponin I is increased after interventional clo-sure of atrial septal defects. Catheter Cardiovasc Interv 2003; 58: 124–9.
  • Tarnok A, Bocsi J, Osmancik P, Hausler HJ, Schneider P, Dahnert I. Cardiac troponin I release after transcatheter atrial septal defect closure depends on occluder size but not on patient’s age. Heart 2005; 91: 219–22.
  • Anzai H, Child J, Natterson B, Krivokapich J, Fishbein MC, Chan VK, Tobis JM. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004; 93: 426–31.
  • Spies C, Strasheim R, Timmermanns I, Schraeder R. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Eur Heart J 2006; 27: 365–71.
  • Brandt RR, Neumann T, Neuzner J, Rau M, Faude I, Hamm CW. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echo cardiogr 2002; 15: 1094–8.
  • Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving con-cepts. J Am Coll Cardiol 2005; 46: 937–54.
  • Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravas-tatin therapy in hyperlipidemia: effects on thrombus forma-tion and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294–304.
  • Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985; 54: 442–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.